27^th International Diabetes and Healthcare Conference

Despite the known benefits of a healthy lifestyle, many individuals find it hard to maintain such a lifestyle in the modern world, which facilitates sedentary behavior and overeating. Consequently, the prevalence of type 2 diabetes mellitus is predicted to increase dramatically over the coming years. To counteract the resulting impact on morbidity and mortality of the disease, a tremendous number of new treatments available for diabetes was poured into the market Research lines in diabetes can be grouped into three main categories: technological, biological, and pharmacological with the latter category, pharmacological research, appears the most effective for significantly reducing the burden of type 2 diabetes mellitus. However, the success of antidiabetic medication has also been limited by their mechanism of action and side effects. A big number of promising new drugs were developed to achieve newer antidiabetic medication including oral insulin, gene therapy, the incretins, dipeptidyl peptidase-4 inhibitors, peroxisome proliferator-activated receptor inhibitors,and sodium–glucose cotransporter inhibitors to treat Type 2 diabetes mellitus. However, the up to date, current standard of care for diabetes management is not enough for long run benefits to diabetic patients. The aim of my talk is to provide a brief overview of current antidiabetic drugs & updates on diabetes management for clinical usage.